NRX Pharmaceuticals, Inc. (NRXP) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, NRX Pharmaceuticals, Inc.'s filing signal turned positive.

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders, including suicidal depression, chronic pain, PTSD, and schizophrenia. The company's drug development centers on enhancing neuroplasticity by modulating the NMDA receptor, with three lead candidates: NRX-100 (ketamine), KETAFREETM (generic ketamine), and NRX-101 (D-cycloserine and lurasidone combination). NRx also operates HOPE Therapeutics, a medical services company offering interventional psychiatry care, which acquired Dura Medical in September 2025 and expanded its network with Cohen and Associates in October 2025. HOPE Therapeutics aims to provide integrated psychiatric treatment using neuroplastic drugs, TMS, digital therapeutics, and hyperbaric therapy, with plans to expand its clinic footprint.

Revenue is primarily driven by patient services from its HOPE Therapeutics subsidiary, which operates interventional psychiatry clinics. Future revenue is expected from the commercialization of its drug candidates, NRX-100, KETAFREETM, and NRX-101, upon FDA approval.